Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

PFE•2026-08-04

Quarterly profit beats estimates

Aug. 4 (Reuters) - Pfizer beat Wall Street estimates for second-quarter profit on Tuesday, driven by strong demand for its blood thinner, Eliquis.

On an adjusted basis, the company reported a profit of 77 cents per share, compared with analysts' estimates of 68 cents per share, according to data compiled by LSEG.

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Quarterly profit beats estimates

Related News

FIS tumbles after lower-than-expected Q3 revenue, profit forecasts

FEMSA <FEMSAUBD.MX>: BofA Global Research Raises Price Objective to MXN270.00 From MXN215.00

Intensity Therapeutics schedules Q2 financial results conference call

Imunon schedules Q2 results, business update conference call

NRG Energy misses quarterly profit estimates as interest costs rise